| __timestamp | Biogen Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1171036000 | 9335772 |
| Thursday, January 1, 2015 | 1240400000 | 999000 |
| Friday, January 1, 2016 | 1478700000 | 978000 |
| Sunday, January 1, 2017 | 1630000000 | 952000 |
| Monday, January 1, 2018 | 1816300000 | 956000 |
| Tuesday, January 1, 2019 | 1955400000 | 8122999 |
| Wednesday, January 1, 2020 | 1805200000 | 8712000 |
| Friday, January 1, 2021 | 2109700000 | 13980000 |
| Saturday, January 1, 2022 | 2278300000 | 21135000 |
| Sunday, January 1, 2023 | 2533400000 | 10755000 |
| Monday, January 1, 2024 | 0 |
Infusing magic into the data realm
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of industry leaders is crucial. Biogen Inc., a stalwart in the biotech sector, has consistently demonstrated robust cost management. From 2014 to 2023, Biogen's cost of revenue surged by approximately 116%, reflecting its strategic investments and operational efficiency. In contrast, Iovance Biotherapeutics, Inc., a rising star in the field, has shown a more modest increase in cost of revenue, growing by about 15% over the same period. This disparity highlights the contrasting scales and operational strategies of these two companies. While Biogen's costs reflect its expansive operations, Iovance's figures suggest a more focused, perhaps nascent, stage of growth. As the biotech industry continues to innovate, these financial insights offer a glimpse into the strategic priorities and market positioning of its key players.
Cost of Revenue Trends: AbbVie Inc. vs Iovance Biotherapeutics, Inc.
Novartis AG vs Biogen Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bristol-Myers Squibb Company and Iovance Biotherapeutics, Inc.
Takeda Pharmaceutical Company Limited vs Biogen Inc.: Efficiency in Cost of Revenue Explored
Takeda Pharmaceutical Company Limited vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Biogen Inc. and BeiGene, Ltd.
Cost of Revenue: Key Insights for Biogen Inc. and Incyte Corporation
Cost of Revenue: Key Insights for Biogen Inc. and Viatris Inc.
Cost of Revenue: Key Insights for Biogen Inc. and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: PTC Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Wave Life Sciences Ltd.